Show simple item record

dc.contributor.authorBody, R
dc.contributor.authorCarlton, E
dc.contributor.authorSperrin, M
dc.contributor.authorLewis, PS
dc.contributor.authorBurrows, G
dc.contributor.authorCarley, S
dc.contributor.authorMcDowell, G
dc.contributor.authorBuchan, I
dc.contributor.authorGreaves, K
dc.contributor.authorMackway-Jones, K
dc.description.abstractBackground: The original Manchester Acute Coronary Syndromes model (MACS) 'rules in' and 'rules out' acute coronary syndromes (ACS) using high sensitivity cardiac troponin T (hs-cTnT) and heart-type fatty acid binding protein (H-FABP) measured at admission. The latter is not always available. We aimed to refine and validate MACS as Troponin-only Manchester Acute Coronary Syndromes (T-MACS), cutting down the biomarkers to just hs-cTnT. Methods: We present secondary analyses from four prospective diagnostic cohort studies including patients presenting to the ED with suspected ACS. Data were collected and hs-cTnT measured on arrival. The primary outcome was ACS, defined as prevalent acute myocardial infarction (AMI) or incident death, AMI or coronary revascularisation within 30 days. T-MACS was built in one cohort (derivation set) and validated in three external cohorts (validation set). Results: At the 'rule out' threshold, in the derivation set (n=703), T-MACS had 99.3% (95% CI 97.3% to 99.9%) negative predictive value (NPV) and 98.7% (95.3%-99.8%) sensitivity for ACS, 'ruling out' 37.7% patients (specificity 47.6%, positive predictive value (PPV) 34.0%). In the validation set (n=1459), T-MACS had 99.3% (98.3%-99.8%) NPV and 98.1% (95.2%-99.5%) sensitivity, 'ruling out' 40.4% (n=590) patients (specificity 47.0%, PPV 23.9%). T-MACS would 'rule in' 10.1% and 4.7% patients in the respective sets, of which 100.0% and 91.3% had ACS. C-statistics for the original and refined rules were similar (T-MACS 0.91 vs MACS 0.90 on validation). Conclusions: T-MACS could 'rule out' ACS in 40% of patients, while 'ruling in' 5% at highest risk using a single hs-cTnT measurement on arrival. As a clinical decision aid, T-MACS could therefore help to conserve healthcare resources.
dc.publisherBMJ Publishing Group
dc.relation.ispartofjournalEmergency Medicine Journal
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchHealth services and systems
dc.subject.fieldofresearchPublic health
dc.subject.keywordsacute myocardial infarct
dc.subject.keywordscardiac care, diagnosis
dc.titleTroponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: Single biomarker re-derivation and external validation in three cohorts
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationBody, R; Carlton, E; Sperrin, M; Lewis, PS; Burrows, G; Carley, S; McDowell, G; Buchan, I; Greaves, K; Mackway-Jones, K, Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: Single biomarker re-derivation and external validation in three cohorts, Emergency Medicine Journal, 2017, 34 (6), pp. 349-356
gro.hasfulltextNo Full Text
gro.griffith.authorGreaves, Kim

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record